Molecularly Targeted Agents as Radiosensitizers in Cancer Therapy—Focus on Prostate Cancer

@inproceedings{Alcorn2013MolecularlyTA,
  title={Molecularly Targeted Agents as Radiosensitizers in Cancer Therapy—Focus on Prostate Cancer},
  author={Sara R Alcorn and Amanda J. Walker and Nishant Gandhi and Amol K Narang and Aaron T. Wild and Russell Hales and Joseph M. Herman and Danny Y. Song and Theodore L Deweese and Emmanuel S Antonarakis and Phuoc T. Tran},
  booktitle={International journal of molecular sciences},
  year={2013}
}
As our understanding of the molecular pathways driving tumorigenesis improves and more druggable targets are identified, we have witnessed a concomitant increase in the development and production of novel molecularly targeted agents. Radiotherapy is commonly used in the treatment of various malignancies with a prominent role in the care of prostate cancer patients, and efforts to improve the therapeutic ratio of radiation by technologic and pharmacologic means have led to important advances in… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
8 Extracted Citations
175 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-8 of 8 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 175 references

A Multi-institutional Phase I and Biomarker Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer

  • D. A. Hamstra
  • Available online: http://clinicaltrials.gov/show…
  • 2013
1 Excerpt

A Phase I Trial to Evaluate Acute and Late Toxicities of Concurrent Treatment With Everolimus (RAD001) and Radio-Hormonotherapy in High-risk Prostate Cancer

  • D. Azria
  • Available online: http://clinicaltrials.gov/show…
  • 2013
1 Excerpt

Similar Papers

Loading similar papers…